Ryan Schubert is currently the Senior Director in Clinical Development and Head of Translational Medicine at Asceneuron. During his academic training at Stanford and UCSF, Ryan developed novel biomarkers and approaches to identify the targets and triggers of neuroinflammatory diseases like multiple sclerosis and acute flaccid myelitis. Ryan is passionate about scientific discoveries that can be transformed into innovative drug companies, so that patients with unmet needs benefit from the latest advances in research. At Asceneuron, Ryan is responsible for implementing biomarkers in the company’s clinical trials and is a key member of the clinical team bringing Asceneuron’s lead compounds to patients with neurodegenerative diseases.